Trial Profile
Phase I/II Study of Niraparib With Radiotherapy for Treatment of Metastatic Invasive Carcinoma of the Cervix
Status:
Suspended
Phase of Trial:
Phase I/II
Latest Information Update: 16 Aug 2023
Price :
$35
*
At a glance
- Drugs Niraparib (Primary) ; Carboplatin; Paclitaxel
- Indications Adenocarcinoma; Cervical cancer; Squamous cell cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms NIVIX
- 19 Apr 2023 Planned primary completion date changed from 1 Mar 2023 to 1 Nov 2023.
- 07 Dec 2022 Status changed from recruiting to suspended.
- 22 Apr 2021 Planned number of patients changed from 20 to 24.